Comparison of efficacy and tolerability of felodipine ER monotherapy and combined felodipine ER and losartan in patients with essential hypertension

巴建明,李新华,宋亚香,朱开元

DOI: https://doi.org/10.3969/j.issn.0253-9934.2003.06.009

2003-01-01

Abstract:Objective To compare the efficacy and tolerability of felodipine ER monotherapy and combined felodipine ER and losartan in patients with essential hypertension. Methods 60 patients with essential hypertension were randomly allocated to 10 week treatment with either monotherapy (5 mg or 10 mg felodipine ER, once daliy) , or combined therapy (5 mg felodipine ER + 50 mg losartan, once daliy ). Blood pressure and the adverse reactions were assessed every 2 weeks. Effective renal plasma flow(ERPF) was measured at the beginning and the end of the treatment. Results After 2 weeks treatment, the three groups had significant reduction of systolic/diastolic blood pressure (BP) in sitting posture. There were no significant differences between the three groups. Reduction of systolic/diastolic BP in sitting posture at 10 weeks was more significant with 10 mg felodipine monotherapy group than the other two groups. The adverse effects occurred less oftenly in patients taking combined therapy than in those taking felodipine alone. Some differences in ERPF was observed in either of the three groups, but this difference was not significant. Conclusion Our study shows that combined therapy is better tolerated than long term monotherapy in higher dosage, either felodipine monotherapy or combined with losartan can maintain the ERPF in patients with essential hypertension.